SCHEMBL158111

SCHEMBL158111

COC(=O)c1ccc(C)cc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.57
MAPT P10636 3/20 0.56
NR4A2 P43354 2/20 0.53
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.52
HPGD P15428 2/20 0.52
GAA P10253 2/20 0.52
GLA P06280 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
ATM Q13315 1/20 0.52
HSD17B10 Q99714 1/20 0.52
CYP46A1 Q9Y6A2 1/20 0.51
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
TAS1R2 Q8TE23 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA7 P43166 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30409057 0.98 TDP1 (0.55) TDP1MAPTNR4A2ALDH1A1KDM4E
SCHEMBL30514840 0.93 KDM4E (0.51) TDP1MAPTNR4A2ALDH1A1KDM4E
SCHEMBL1206018 0.85 CYP46A1 (0.57) TDP1MAPTNR4A2ALDH1A1KDM4E
SCHEMBL6113261 0.85 KMT2A (0.49) TDP1MAPTTAS1R3TAS1R1TAS1R2
SCHEMBL124710 0.85 KMT2A (0.49) TDP1MAPTTAS1R3TAS1R1TAS1R2
SCHEMBL29462647 0.85 KMT2A (0.49) TDP1MAPTTAS1R3TAS1R1TAS1R2
SCHEMBL19256975 0.84 TAS1R3 (0.48) TDP1MAPTNR4A2TAS1R3TAS1R1
SCHEMBL45823 0.83 KDM4E (0.67) TDP1MAPTALDH1A1KDM4EHPGD
SCHEMBL2884545 0.83 KDM4E (0.52) TDP1MAPTNR4A2ALDH1A1KDM4E
SCHEMBL8527590 0.83 KMT2A (0.48) TDP1MAPTTAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119868367-A Bigeminal compound pharmaceutical composition for treating glaucoma and application thereof 宁夏康亚药业股份有限公司 2025-04-25 CN disclosed
WO-2024199063-A1 PHOSPHORUS OR SULFUR-CONTAINING MACROCYCLE AND USE THEREOF 浙江养生堂天然药物研究所有限公司 2024-10-03 WO disclosed
CN-118724963-A Macrocyclic compounds containing phosphorus or sulfur and use thereof 浙江养生堂天然药物研究所有限公司 2024-10-01 CN disclosed
CN-117532524-A Composite diamond micro powder for diamond wire saw and preparation process thereof 弘元超硬材料(河南)有限公司 2024-02-09 CN disclosed
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2023-10-19 US disclosed
US-20230322803-A1 SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER BRISTOL MYERS SQUIBB CO (US) 2023-10-12 US disclosed
CN-110494138-B Pharmaceutical preparation 兴和株式会社 2023-07-11 CN disclosed
CN-116139138-A Heterocyclic modulators of lipid synthesis 3-V生物科学股份有限公司 2023-05-23 CN disclosed
CN-116063200-A Isoxazoline pesticide fluorine Lei Lana intermediate for pets and preparation method thereof 华南理工大学 2023-05-05 CN disclosed
US-20230111853-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION ORIONIS BIOSCIENCES, INC. 2023-04-13 US disclosed
US-4694006-A Acyl- or acyloxymethyl-allopurinol prodrugs A/S GEA (DK) 1987-09-15 US disclosed
US-4654371-A ANTI-OBESITY, HYPOGLYCEMIA AGENTS BEECHAM GROUP P.L.C. (GB) 1987-03-31 US disclosed
US-4613208-A ELECTROOPTICS; ULTRAVIOLET RADIATION STABILITY; QUICK RESPONSE HOFFMANN-LA ROCHE INC. (US) 1986-09-23 US disclosed
US-4595521-A In liquid crystalline carrier HOFFMANN-LA ROCHE INC. (US) 1986-06-17 US disclosed
US-4550981-A Liquid crystalline esters and mixtures HOFFMANN-LA ROCHE INC. (US) 1985-11-05 US disclosed
EP-0148883-A1 ALLOPURINOL PRODRUGS. GEA AS (DK) 1985-07-24 EP disclosed
WO-1985000368-A1 ALLOPURINOL PRODRUGS A/S GEA (DK) 1985-01-31 WO disclosed
US-4478849-A HYPERGLYCEMIC AGENTS BEECHAM GROUP LIMITED (GB) 1984-10-23 US disclosed
EP-0006735-B1 SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE BEECHAM GROUP PLC (GB) 1983-06-15 EP disclosed
EP-0006735-A1 Secondary amines, their preparation, pharmaceutical compositions containing them and their use BEECHAM GROUP PLC (GB) 1980-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230111853-A1 COMPOUNDS MODULATING PROTEIN RECRUITMENT AND/OR DEGRADATION CRBN, STUB1, ADRM1 TDP1 2765/4885MAPT 402/4885NR4A2 1219/4885
US-20230331681-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN TDP1 2798/4885MAPT 2938/4885NR4A2 429/4885
US-20230322803-A1 SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER DDX21, HRAS, RPL17 TDP1 1801/4885MAPT 3829/4885NR4A2 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.